SCI时时刷

search
Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International ...
Targeting IL-23 for IBD: Rationale and Progress to Date
Targeting IL-23 for IBD: Rationale and Progress to Date
Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, comprises multiple complex immune-medi...
Leniolisib: First Approval
Leniolisib: First Approval
Leniolisib (JOENJA®) is an oral selective phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor being developed by P...
Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
Guideline-directed medical therapy (GDMT) is the cornerstone of pharmacological therapy for patients with heart failure wi...
Acute Graft-versus-Host Disease: An Update on New Treatment Options
Acute Graft-versus-Host Disease: An Update on New Treatment Options
Acute graft-versus-host disease (GVHD) occurs in approximately 50% of patients and remains a primary driver of non-relapse...
Correction to: Eftrenonacog Alfa: A Review in Haemophilia B
Correction to: Eftrenonacog Alfa: A Review in Haemophilia B
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International ...
New Pharmacologic Approaches to the Treatment of Bipolar Depression
New Pharmacologic Approaches to the Treatment of Bipolar Depression
Depression is the most commonly experienced mood state over the life span in individuals with bipolar disorder (BD) and is...
Zavegepant: First Approval
Zavegepant: First Approval
Zavegepant is a third generation, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being develop...
The Effect of Biological Treatment on Fatigue in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
The Effect of Biological Treatment on Fatigue in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Fatigue is a frequent complaint in patients with inflammatory bowel disease. Biological drugs have demonstrated beneficial...
Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics
Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics
As clinical use of currently available opioid analgesics is often impeded by dose-limiting adverse effects, such as abuse ...
Rezafungin: First Approval
Rezafungin: First Approval
Rezafungin (Rezzayo™), an intravenous once-weekly echinocandin that inhibits 1,3-β-d-glucan synthase, is being ...
Baricitinib for the Treatment of Alopecia Areata
Baricitinib for the Treatment of Alopecia Areata
Alopecia areata (AA) is a relapsing, chronic, immune-mediated disease characterized by nonscarring, inflammatory hair loss...
Results from Expanded Access Programs: A Review of Academic Literature
Results from Expanded Access Programs: A Review of Academic Literature
Although expanded access is an increasingly used pathway for patients to access investigational medicine, little is known ...
Correction to: Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study
Correction to: Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study
Department of Otolaryngology-Head and Neck Surgery, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanThomas Yen-Tin...
Antibiotics and Probiotics for Irritable Bowel Syndrome
Antibiotics and Probiotics for Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a disorder of a gut-brain interaction characterised by abdominal pain and a change in st...
Cipaglucosidase Alfa: First Approval
Cipaglucosidase Alfa: First Approval
Cipaglucosidase alfa (Pombiliti™) is a recombinant human acid α-glucosidase (GAA) product being developed by Am...
Retifanlimab: First Approval
Retifanlimab: First Approval
Retifanlimab (retifanlimab-dlwr; ZYNYZTM) is a programmed cell death 1 receptor-blocking antibody that is being developed ...
Trofinetide: First Approval
Trofinetide: First Approval
Trofinetide (DAYBUE™), an oral, small molecule, synthetic analog of glycine-proline-glutamate [GPE; the N-terminal t...
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study
To explore the association between human papillomavirus (HPV) vaccination and risk of coronavirus disease 2019 (C...
Correction to: Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’
Correction to: Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’
Authors and AffiliationsSchool of Pharmacy, International Medical University, 126, Jalan Jalil Perkasa, Bukit Jalil, Kuala...
Androgenetic Alopecia: Therapy Update
Androgenetic Alopecia: Therapy Update
Androgenetic alopecia (AGA), also known as male pattern hair loss (MPHL) or female pattern hair loss (FPHL), is the most c...
Ravulizumab: A Review in Generalised Myasthenia Gravis
Ravulizumab: A Review in Generalised Myasthenia Gravis
Ravulizumab (ULTOMIRIS®) is the first long-acting complement C5 inhibitor (administered intravenously every 8 weeks) ...
Omaveloxolone: First Approval
Omaveloxolone: First Approval
Omaveloxolone (SKYCLARYS™) is an orally active, small molecule semi-synthetic triterpenoid drug that increases antio...
The Role of Vitamin D in Health and Disease: A Narrative Review on the Mechanisms Linking Vitamin D with Disease and the Effects of Supplementation
The Role of Vitamin D in Health and Disease: A Narrative Review on the Mechanisms Linking Vitamin D with Disease and the Effects of Supplementation
Vitamin D insufficiency or deficiency (VDD) is a very prevalent condition in the general population. Vitamin D is necessar...
Authors’ Reply to Chia Siang Kow et al.: Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?’
Authors’ Reply to Chia Siang Kow et al.: Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?’
Kow CS, Ramachandram DS, Hasan SS. Comment on: ‘Should we interfere with the interleukin-6 receptor during COVID-19: what ...
Interleukin-6 Receptor Inhibitors and long COVID
Interleukin-6 Receptor Inhibitors and long COVID
Funding No external funding was used in the preparation of this art...
Eftrenonacog Alfa: A Review in Haemophilia B
Eftrenonacog Alfa: A Review in Haemophilia B
Eftrenonacog alfa (Alprolix®) is an extended half-life recombinant factor IX (rFIX)-Fc fusion protein (hereafter refe...
Keverprazan Hydrochloride: First Approval
Keverprazan Hydrochloride: First Approval
Keverprazan hydrochloride (凯普拉生) is a potassium ion competitive acid blocker that is being dev...
Innovation in Targeted Intra-articular Therapies for Osteoarthritis
Innovation in Targeted Intra-articular Therapies for Osteoarthritis
Osteoarthritis is the most common chronic joint disease characterized by progressive damage to the joints, leading to pain...